Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

Pulmicort sales declined 4% to $138 million. Fasenra recorded sales of $436 million in the quarter, up 13% year over year, ...

In this video, Juan Carlos Cardet, MD, of the University of South Florida (USF) Health Morsani College of Medicine in Tampa, ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...

AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca’s FASENRA ...

AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the current standard of care, GSK’s Nucala (mepolizumab), in patients ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a ...